Pembrolizumab approved for triple-negative breast cancerNovember 16, 2020Breast CancerMetastatic Breast Cancer
Divergent findings with paclitaxel and nab-paclitaxel in TNBCSeptember 28, 2020Breast CancerMetastatic Breast Cancer
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020Breast CancerMetastatic Breast Cancer
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 resultsSeptember 9, 2020Breast CancerMetastatic Breast Cancer
First guideline on NGS testing in cancer, from ESMOAugust 28, 2020Breast CancerMetastatic Breast Cancer
Novel SERD, LSZ102, shows promise for pretreated ER+ breast cancerJune 30, 2020Breast CancerMetastatic Breast Cancer
Key Studies in Metastatic Breast Cancer From ASCO 2020June 22, 2020Breast CancerMetastatic Breast Cancer
‘A good and peaceful death’: Cancer hospice during the pandemicJune 5, 2020Breast CancerMetastatic Breast Cancer
TILs and PET-CT can predict pCR in HER2-positive metastatic breast cancerJune 2, 2020Breast CancerMetastatic Breast Cancer
Treating primary tumor doesn’t improve OS in stage IV breast cancerJune 1, 2020Breast CancerMetastatic Breast Cancer
Pyrotinib bests lapatinib in HER2+ metastatic breast cancerMay 31, 2020Breast CancerMetastatic Breast Cancer
Expanding the role of PARP inhibitors in breast cancerMay 31, 2020Breast CancerMetastatic Breast Cancer
